Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
25 Mar 2022
Healthcare in Warzones: Ukraine
This week, Jonathan focuses on the ongoing conflict in Ukraine, discussing the disastrous impacts of war, from environmental consequences to effects on healthcare systems.
Claire Skentelbery, Director General, EuropaBio
Bonus episode this week for GOLD podcast, featuring a full feature-length interview with Claire Skentelbery, Director General, EuropaBio. Stream now!
FDA approves first-in-class cancer checkpoint inhibitor
A new type of checkpoint inhibitor to treat unresectable or metastatic melanoma has been approved by the FDA.
Industry welcomes UK-wide commitment to genomic research
Better genomic testing and access to clinical trials have been prioritised and agreed by the UK government and devolved administrations. Read for more details.
The risks, rewards and future potential of biotechnology
In this episode, Marc and Helena have a chat about biotech with special guest Claire Skentelbery, Director General of EuropaBio.
10
Mins
22 Mar 2022
Targeting the Immune System and Beyond: The Potential for Safe and Durable Responses in Higher-Risk Myelodysplastic Syndromes with Immuno-Myeloid Therapy
The hypomethylating agents (HMA), azacitidine and decitabine, are currently regarded as the standard of care for patients with…
March 2022
EMJ Hematology 10 [Supplement 4] 2022
Myelodysplastic syndromes (MDS) are a rare group of blood disorders that can result in symptoms spanning from fatigue to easy bruising and bleeding. Based on a symposium that was part of the International Congress on Myelodysplastic Syndromes by the MDS Foundation, this article provides an overview of MDS.
7
Mins
22 Mar 2022
Interview: David Oliver
David Oliver shared his thoughts with EMJ on his leadership and policy experience, his passion for advocacy in healthcare, and his work in…
March 2022
EMJ 7.1 2022
Welcome to our first flagship EMJ journal of the year that has a mini-focus on COVID-19, sharing case studies alongside our article…
5
Mins
22 Mar 2022
Science Versus COVID-19: What Have We Learnt So Far?
TWO YEARS AGO, the COVID-19 pandemic emerged and swept through the world, going on to have a profound human and health toll…
←
1
2
3
…
430
431
432
433
434
435
436
…
1,049
1,050
1,051
→